Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris

LONDON, December 17, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Novavax Inc. (NASDAQ: NVAX), Amarin Corporation PLC (NASDAQ: AMRN), Immunomedics Inc. (NASDAQ: IMMU), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 16, 2014, the NASDAQ Composite ended at 4,547.83, down 1.24%, the Dow Jones Industrial Average declined 0.65%, to finish the day at 17,068.87, and the S&P 500 closed at 1,972.74, down 0.85%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, while the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

On Tuesday, shares in Celgene Corp. fluctuated between $108.26 and $113.59 before ending the session 1.60% lower at $110.09. The stock reported a trading volume of 7.02 million shares, above its three months average volume of 5.05 million shares. Shares of the company traded at a PE ratio of 50.57. Celgene Corp.'s shares have advanced 5.80% in the last one month, 18.93% in the previous three months and 30.31% on YTD basis. The company's stock closed above its 50-day and 200-day moving averages of $104.58 and $87.93, respectively. Moreover, shares of Celgene Corp. have a Relative Strength Index (RSI) of 52.25. Sign up and read the free notes on CELG at:

http://get.Investor-Edge.com/pdf/?c=Celgene&d=17-Dec-2014&s=CELG

Novavax Inc.'s stock edged 0.53% lower, to close the day at $5.60. The stock recorded a trading volume of 2.55 million shares, below its three months average volume of 3.98 million shares. The stock oscillated between $5.51 and $5.81 during the session. Over the last one month and over the past three months, Novavax Inc.'s shares have gained 6.06% and 24.44%, respectively. Further, the stock has advanced 9.38% since the start of this year. The company's stock closed above its 50-day and 200-day moving averages. The stock's 50-day moving average of $5.15 is above its 200-day moving average of $4.70. Additionally, Novavax Inc. has an RSI of 57.07. The complimentary notes on NVAX can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Novavax&d=17-Dec-2014&s=NVAX

On Tuesday, shares in Amarin Corp. PLC recorded a trading volume of 1.03 million shares, lower than its three months average volume of 2.04 million shares. The stock ended the day at $1.03, which was 1.90% below its previous day's closing of $1.05, and registered an intraday range of $0.97 and $1.05. Although Amarin Corp. PLC's shares have surged 8.44% in the last one month, it has declined 0.96% in the previous three trading sessions and 47.72% on YTD basis. The company's shares closed below its 50-day and 200-day moving averages of $1.04 and $1.47, respectively. Furthermore, shares of Amarin Corp. PLC have an RSI of 45.85. Register for free on Investor-Edge and access the latest research on AMRN at:

http://get.Investor-Edge.com/pdf/?c=Amarin&d=17-Dec-2014&s=AMRN

Immunomedics Inc.'s stock edged 0.48% higher, to close Tuesday's session at $4.23, after oscillating between $4.08 and $4.36. The stock recorded a trading volume of 0.62 million shares, below its three months average volume of 0.75 million shares. Over the last one month and the previous three months, Immunomedics Inc.'s shares have surged 12.50% and 29.36%, respectively. However, the stock has lost 8.04% on YTD basis. The company's stock closed above its 50-day and 200-day moving averages. The stock's 50-day moving average of $3.85 is above its 200-day moving average of $3.72. Further, Immunomedics Inc.'s stock has an RSI of 52.80. The complete research on IMMU is available for free at:

http://get.Investor-Edge.com/pdf/?c=Immunomedics&d=17-Dec-2014&s=IMMU

Aeterna Zentaris Inc.'s stock finished Tuesday's session 1.66% higher at $0.62. A total of 0.57 million shares were traded, which was much below its three months average volume of 2.01 million shares. The stock moved between $0.58 and $0.64 during the session. Aeterna Zentaris Inc.'s shares have advanced 8.79% in the previous three trading sessions and 10.73% in the last one month. However, from the beginning of 2014, the stock has plummeted 55.07%. The company's shares closed below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $1.12 is greater than its 50-day moving average of $0.86. Aeterna Zentaris Inc.'s stock has an RSI of 43.02. Free in depth research on AEZS is available at:

http://get.Investor-Edge.com/pdf/?c=Aeterna%20Zentaris&d=17-Dec-2014&s=AEZS

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED